Non-genomic action of beclomethasone dipropionate on bronchoconstriction caused by leukotriene C4 in precision cut lung slices in the horse

BMC Veterinary Research

Bernhard Ohnesorge²  Manfred Kietzmann¹  Frank Niedorf¹  Ann-Kristin Barton²  Maria Fugazzola¹ 

[1] University of Veterinary Sciences Hanover, Institute for Pharmacology, Pharmacy and Toxicology, Hanover, Germany;University of Veterinary Sciences Hanover, Clinic for Horses, Hanover, Germany

关键词: PCLS;    Precision-cut lung slices;    RAO;    Recurrent airway obstruction;    Non-genomic membrane receptors;    Leukotriene;    Horse;    Beclomethasone;   

Others  :  1119727
DOI  :  10.1186/1746-6148-8-160

 received in 2011-11-29, accepted in 2012-08-13,  发布年份 2012

【 摘 要 】

Background

Glucocorticoids have been proven to be effective in the therapy of recurrent airway obstruction (RAO) in horses via systemic as well as local (inhalative) administration. Elective analysis of the effects of this drug on bronchoconstriction in viable lung tissue offers an insight into the mechanism of action of the inflammatory cascade occurring during RAO which is still unclear. The mechanism of action of steroids in treatment of RAO is thought to be induced through classical genomic pathways. We aimed at electively studying the effects of the glucocorticoid beclomethasone dipropionate on equine precision-cut lung slices (PCLS).

PCLS were used to analyze ex-vivo effects of beclomethasone on inhibiting bronchoconstriction in the horse. The inhibiting effect was measured through instillation of a known mediator of inflammation and bronchoconstriction, leukotriene C₄. For this, the accessory lobes of 13 horses subjected to euthanasia for reasons unrelated to the respiratory apparatus were used to obtain viable lung slices.

Results

After 30 minutes of PCLS incubation, beclomethasone showed to significantly inhibit the contraction of the bronchioles after instillation with leukotriene C₄. The EC₅₀ values of the two contraction curves (LTC₄ with and without BDP) differed significantly from each other (p = 0.002). The possibility of a non-genomic rapid mechanism of action seems likely since transcriptional activities require a longer lag period.

Conclusions

In human neuroendocrinology, high levels of glucocorticoids have been proven to function via a non-genomic mechanism of membrane receptors. The concentration of beclomethasone used on the lung slices in our study can be considered as high. This allows speculation about similar rapid non-genomic mechanisms of high-dosage inhaled glucocorticoids in the lower airways of horses. However, further assessment on a molecular basis is needed to confirm this.

【 授权许可】

   
2012 Fugazzola et al.; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

Figure 3.

【 参考文献 】

• [1]Barnes PJ: Molecular mechanisms of glucocorticoid action in asthma. Pulmonary Pharmacology & Therapeutics 1997, 10:1-65. 3–19
• [2]Alangari A: Genomic and non-genomic actions of glucocorticoids in asthma. Annals of Thoracic Medicine 2010, 5:133-139.
• [3]Reichardt HM, Tuckermann JP, Bauer A, Schutz G: Molecular genetic dissection of glucocorticoid receptor function in vivo. Zeitschrift Fuer Rheumatologie 2000, 59:1-5.
• [4]Gibson PG, Saltos N, Fakes K: Acute anti-inflammatory effects of inhaled budesonide in asthma: a randomized controlled trial. Am J Respir Crit Care Med 2001, 163:32-36.
• [5]Lavoie JP: Heaves (recurrent airway obstruction): practical management of acute episodes and prevention of exacerbations Current Therapy in Equine Medicine2003. Edited by Robinson ME, Sprayberry KA. St. Louis, Saunders;
• [6]Hanania NA: The impact of inhaled corticosteroid and long-acting beta-agonist combination therapy on outcomes in COPD. Pulm Pharmacol Ther 2008, 21:540-550.
• [7]Corcoran BM, Mair TS, Taylor DJ: Drugs used in the treatment of disorders of the respiratory system. The Veterinary Formulary, sixth edition 2005. The Pharmaceutical Press, London; 2005.
• [8]Leguilette R: Recurrent airway obstruction—heaves. The Veterinary Clinics Equine Practice 2003, 19:63-86.
• [9]Couetil LL, Art T, Demoffarts B, Becker M, Melotte D, Jaspar F, Bureau F, Lekeux P: Effect of beclomethasone dipropionate and dexamethasone isonicotinate on lung function, bronchoalveolar lavage fluid cytology, and transcription factor expression in airways of horses with recurrent airway obstruction. J Vet Intern Med 2006, 20:399-406.
• [10]Davis E, Rush BR, Equine RAO: Pathogenesis and patient management. Veterinary Clinics of North America: Equine Practice 2002, 18:453-467.
• [11]Ainsworth DM, Cheetam J: Disorders of the respiratory system. In Equine Internal Medicine. third edition. Edited by Reed , Warwick , Sellon . Saunders, St. Lois; 2010:340-344.
• [12]Nagase T, Fukuchi Y, Dallaire MJ, Martin JG, Ludwig MS: In vitro airway and tissue response to antigen in sensitized rats - role of serotonin and leukotriene D-4. Am J Respir Crit Care Med 1995, 152:81-86.
• [13]Drazen JM: Leukotrienes as mediators of airway obstruction. Am J Respir Crit Care Med 1998, 158:193-200.
• [14]Lavoie JP, Leguillette R, Pasloske K, Charette L, Sawyer N, Guay D, Murphy T, Hickey GJ: Comparison of effects of dexamethasone and the leukotriene D4 receptor antagonist L-708,738 on lung function and airway cytologic findings in horses with recurrent airway obstruction. Am J Vet Res 2002, 63:579-585.
• [15]Lindberg A, Robinson NE, Naesman-glaser B, Jensen-waern M, Lindrgren JA: Assessment of leukotriene B4 production in leukocytes from horses with recurrent airway obstruction. American Journal of Veterinary Reasearch 2004, 65:289-295.
• [16]Marr K, Lees P, Page CP, Cunningham FM: Inhaled leukotrienes cause bronchoconstriction and neutrophil accumulation in horses. Res Vet Sci 1998, 64:219-224.
• [17]Schwalfenberg B: Untersuchung der Leukotrienwirkung am Pferdebronchus mittels. Tierärztliche Hochschule, Dissertation, Hannover; 2007.
• [18]Barton AK, Niedorf F, Gruber AD, Kietzmann M, Ohnesorge B: Pharmacological studies of bronchial constriction inhibited by parasympatholytics and cilomilast using equine precision-cut lung slices. Berliner und Münchner Tierarztliche Wochenschrift 2010, 123:229-235.
• [19]Vietmeier J, Niedorf F, Baumer W, Martin C, Deegen E, Ohnesorge B, Kietzmann M: Reactivity of equine airways - a study on precision-cut lung slices. Vet Res Commun 2007, 31:611-619.
• [20]Barton AK, Niedorf F, Rohwer J, Kietzmann M, Ohnesorge B: Pilot study on passive sensitization against ovalbumin using equine precision-cut lung slices (PCLS). Pferdeheilkunde 2010, 26:789-796.
• [21]Martin C, Uhilg S: Ullrich: Videomicroscopy of methacholine-induced contraction of individual airways in precision-cut lung slices. Eur Respir J 1996, 9:2479-2487.
• [22]Devillier P: Pharmacology of corticosteroids and ENT diseases: 10 key points. Presse Medicale 2001, 30:59-69.
• [23]Van Dv: Glucocorticoids: mechanisms of action and anti-inflammatory potential in asthma. Mediat Inflamm 1998, 7:229-237.
• [24]Ferguson DC, Hoenig M: Glucocorticoids, mineralocorticoids, and steroid synthesis inhibitors Veterinary Pharmacology and Therapeutics Editor: Adams. Iowa State University Press, Ames (USA); 2001:649-668.
• [25]Croxtall JD, Choudhary Q, RJ FLOWER: Br J Pharmacol. 2000, 130:289-298.
• [26]Muto S, Ebata S, Okada K, Saito T, Asano Y: Glucocorticoid modulates Na+/H + exchange activity in vascular smooth muscle cells by non-genomic and genomic mechanisms. Kidney Int 2000, 57:2319-2333.
• [27]Harvey BJ, Alzamora R, Healy V, Renard C, Doolan CM: Rapid responses to steroid hormones: from frog skin to human colon. An homage to Hans Ussing. Biochimica Et Biophysica Acta-Biomembrane 2002, 1566:116-128.
• [28]Stahn C, Buttgereit F: Genomic and non-genomic effects of glucocorticoids. Nat Clin Pract Rheumatol 2008, 4:525-533.
• [29]Lecoq L, Vincent P, Lavoie-Lamoureux A, Lavoie JP: Genomic and non-genomic effects of dexamethasone on equine peripheral blood neutrophils. Vet Immunol Immunopathol 2009, 128:126-131.
• [30]Wehling M, Losel R: Non-genomic steroid hormone effects: Membrane or intracellular receptors? Journal of Steroid Biochemistry and Molecular Biology 2006, 102:180-183.
• [31]DE Kloet ER, Karst H, Joels M: Corticosteroid hormones in the central stress response: Quick-and-slow. Front Neuroendocrinol 2008, 29:268-272.
• [32]Chanoine F, Grenot C, Heidmann P, Junien JL: Pharmacokinetics of butixocort 21-propionate, budesonide, and beclomethasone dipropionate in the rat after intratracheal, intravenous, and oral treatments. Drug Metabolism and Disposition 1991, 19:546-553.
• [33]Zaitsu M, Hamasaki Y, Aoki Y, Miyazaki S: A novel pharmacologic action of glucocorticosteroids on leukotriene C4 catabolism. Journal of Allergy and Clinical Immunology 2001, 108:122-124.
• [34]Ammann VJ, Vrins AA, Lavoie JP: Effects of inhaled beclomethasone dipropionate on respiratory function in horses with chronic obstructiove pulmonary disease (COPD). Equine Veterinary Journal 1998, 30:152-15734.
• [35]Rush BR, Flaminio MJ, Matson CJ, Hakala JE, Shuman W: Cytologic evaluation of broncho-alveolar lavage fluid from horses with recurrent airway obstruction after aerosol and parenteral administration of beclomethasone dipropionate and dexamethasone, respectively. Am J Vet Res 1998, 59:1033-1038.
• [36]Urbach V, Harvey BJ: Rapid and non-genomic reduction of intracellular [Ca2+] induced by aldosterone in human bronchial epithelium. J Physiol 2001, 537(1):267-27.